You are here : Home > The Lab > A new target for anti-cancer drugs

press release

A new target for anti-cancer drugs

A new mode of action of ellipticine, a molecule known for its anti-cancer properties has been identified by researchers from the CEA, CNRS, Inserm, Institut Curie and Joseph Fourier-University Grenoble 1. They selected derivatives of this molecule capable of specifically targeting the CK2 protein, a protein kinase dysregulated in many cancers, and have demonstrated the antitumor potential of these derivatives. This work, published online by the journal Cancer Research, opens new perspectives for the design of future cancer drugs.

Published on 1 December 2010
Press release available in French.

This crystallographic structure shows how a derivative of ellipticine inhibits protein kinase CK2.

Top page